Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2010

View Archived Issues

Snapshots: New strategies for treating Alzheimer's disease

LC-06 and LC-08 inhibit angiogenesis and tumor survival in vivo

Lu-AA-42202 shows favorable preclinical pharmacological profile

SAR-153192 suppresses tumor growth in vivo and continues evaluation in phase I trial

Innate Pharma begins phase II IPH-2101 trial in smoldering multiple myeloma

Chugai Pharma reports developmental highlights of Q3

New inhibitors of galectin-1 and galectin-3 discovered

GlaxoSmithKline presents new P2X7 receptor antagonists

New inhibitors of E-selectin and chemokine CXCR4 receptor claimed

Merrion and Rebel Pharma enter into feasibility and option agreement

Neuren Pharma develops oral formulation of NNZ-2566

New antagonists claimed of transient receptor potential TRPM8 channel

Profectus BioSciences divulges new NF-kappa-B inhibitors

Katholieke Universiteit Leuven discloses new HIV-1 reverse transcriptase substrates

MAA submitted to EMA for taliglucerase alfa in Gaucher's disease

Pharming reports topline phase II data on Ruconest in asymptomatic HAE

Tribunal finds Johnson & Johnson in breach of agreement with Basilea for ceftobiprole

Takara Bio licenses methylation-specific PCR technology from MDxHealth

Selcia and Gilead to continue liver disease drug discovery collaboration

Takeda applies to change Leuplin dosage and administration for CPP in Japan

Xention raises funds to support atrial fibrillation programs

Johnson & Johnson reports R&D highlights of Q3

AMAG updates Feraheme label following reports of hypersensitivity reactions

Amarin's pivotal phase III MARINE trial of AMR-101 meets primary endpoints

Affymax and Takeda to submit NDA for Hematide to FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...